Danuglipron Cost Explained: Monthly, Yearly, and How to Save

Danuglipron at a glance:

• Drug class: Oral non-peptide GLP-1 receptor agonist (development discontinued)
• Manufacturer: Pfizer
• Route: oral tablet
• Typical frequency: twice daily (in trials)
• Half-life: approximately 4-7 hours (twice daily dosing was tested)
• Receptor target: GLP-1 receptor

Cost is the most common reason people stop Danuglipron, even when it's working. Knowing the full landscape — insurance, savings programs, cash pay, alternatives — usually opens up an option people didn't know they had.

Danuglipron Cash Price

Danuglipron is not consistently available through licensed US pharmacies, so a "list price" is hard to pin down. Compounded or grey-market pricing varies dramatically.

That number is the starting point — what you actually pay depends on:

• Insurance status (commercial, Medicare, Medicaid, uninsured)
• Manufacturer savings programs (where applicable)
• Discount cards (GoodRx, Cost Plus Drug, manufacturer cards)
• Telehealth bundling (some platforms include the drug in a flat monthly fee)
• Pharmacy choice (chain vs independent vs mail-order)

Insurance Coverage

Coverage for Danuglipron depends on the specific plan and the indication being treated. For FDA-approved indications, prior authorization is the most common gate. For off-label use, coverage is generally not available.

The pattern across the GLP-1 / metabolic medication space is: coverage for diabetes is widespread, coverage for weight loss is improving but still inconsistent, and coverage for any off-label use is rare.

Manufacturer Programs

Pfizer runs savings programs for eligible patients. Eligibility usually requires commercial insurance and an active prescription. Patients on Medicare or Medicaid generally aren't eligible.

Cash-Pay and Direct-from-Manufacturer Options

Several manufacturers have introduced direct-to-consumer cash channels for their GLP-1 products in response to coverage gaps. These can lower the cash price meaningfully — see our guide to getting GLP-1 medications for current options.

Total Cost Over a Year

A monthly price of $1,000-$1,500 translates to roughly $10,800-$18,000 per year out of pocket without insurance. That's a real number to plan around — many programs that look attractive at $200/month for the first three months reset to full price after the introductory window.

For weight management, the relevant question is whether to plan around long-term use; for GLP-1 medications, weight regain after stopping is well-documented.

Comparing to Alternatives

With danuglipron's program discontinued, orforglipron is the leading oral GLP-1 in late-stage development. Some of those alternatives may be cheaper, covered when Danuglipron isn't, or just better-suited for a particular case. See our cost comparison pages: linked above.

Bottom Line

The list price for Danuglipron is real but rarely the final number. Build the cost plan into the treatment plan from day one, and revisit it whenever insurance or savings programs change.

Frequently Asked Questions

Related Reading

• What Is Danuglipron? Everything You Should Know Before Starting
• Danuglipron Side Effects: 7 Things to Watch For (and How to Manage Them)
• Danuglipron Outcomes Decoded: Who Responds Best and Why
• Danuglipron for Weight Loss: The Complete 2026 Guide
• Is Retatrutide Right for You? An Evidence-Based Breakdown
• What Nobody Tells You About Retatrutide Side Effects

Sources

• Jastreboff AM et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — Phase 2 Trial. NEJM 2023;389:514.
• Frias JP et al. Efficacy and Safety of Co-Administered Once-Weekly Cagrilintide 2.4 mg with Once-Weekly Semaglutide 2.4 mg. Lancet 2021;397:1736.
• Le Roux CW et al. Survodutide for the Treatment of Obesity — Phase 2. Lancet 2024;403:888.

Pricing changes frequently. The numbers on this page reflect publicly available information as of 2026-04-29 and should be verified at the point of purchase.